Analyst confidence swells following positive FDA alignment on the company's pivotal gene therapy trial for Rett Syndrome.
Permanent J-Code from CMS aims to streamline reimbursement and broaden patient access for its graft-versus-host disease treatment.
Genentech's Tecentriq combination therapy is the first maintenance treatment for extensive-stage small cell lung cancer, a significant advance in a hard-to-treat disease.
Regulators express significant doubts over the company's lead drug candidate, avacopan, sparking a massive investor sell-off.
Reports of a potential foundry deal with its chief rival are seen as a major validation of Intel's manufacturing strategy.
The new oral treatment addresses chronic spontaneous urticaria in patients unresponsive to antihistamines, driving shares up over 2.7%.
A partnership with Samsung and SK Hynix for the ambitious AI infrastructure project is fueling a rally across the chip sector.
The technology giant is raising the price of its top-tier gaming subscription to $29.99, signaling a strategic focus on profitability in its gaming division.